CHIMERIC THERAPEUTICS LIMITED
ASX:CHMPharmaceuticals, Biotechnology & Life SciencesSuspended from quotationToday’s holders own 88.9% of what they think they own, once every option and right converts.
Not rated — the company is suspended from quotation
This company is suspended from ASX quotation. Scoring is paused until it resumes trading. Not rated means no assessment — not low risk.
CHIMERIC THERAPEUTICS LIMITED's share count rose 1412.2% between October 2024 and September 2026, its latest share-count filing, adjusted for a 1-for-100 share consolidation in April 2026, to 147M shares. The company completed nine capital raises in the past 24 months, totalling A$15.8M, most recently a A$4.4M placement and convertible note in December 2025. Options and rights could convert into 18M new shares, a 12.5% overhang, none in the money; the nearest expiry is October 2028. The company's June 2026 quarterly cash report indicated that cash was exhausted at the reported spend rate, and no later cash report is on record, so no funding-runway estimate applies. No proposed securities issues are pending.
Quick answers · 3
When did CHM last raise capital?
The last capital raise in Chimeric Therapeutics's filings is Placement and Convertible Note of $4.4M announced 23 Dec 2025, one of 9 cash raises in 24 months.
How much cash does CHM have?
In its quarterly cash report for the quarter ended 30 June 2026, Chimeric Therapeutics reported $800k of cash and estimated 0.2 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do CHM's options expire?
Unexercised options and rights equal 12.5% of Chimeric Therapeutics's shares on issue; the nearest expiry is Oct 2028.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 29 Sept 2026 | 2A · quoted issue | CHM : ORDINARY FULLY PAID | 147.5M | Appendix 2A |
| 22 Sept 2026 | 2A · quoted issue | CHM : ORDINARY FULLY PAID | 118.1M | Appendix 2A |
| 4 Sept 2026 | 2A · quoted issue | CHM : ORDINARY FULLY PAID | 95.9M | Appendix 2A |
| 27 Aug 2026 | 2A · quoted issue | CHM : ORDINARY FULLY PAID | 81.1M | Appendix 2A |
| 21 Aug 2026 | 2A · quoted issue | CHM : ORDINARY FULLY PAID | 70.8M | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
9 cash raises in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered18.4M · 12.5% of sharesOptions and warrants — they convert when the share price clears their exercise price.At least 3.0M of it states no exercise price — that much cannot be called in or out of the money.
- Condition-triggered72k · 0.0% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 15.4M priced, 3.0M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
At $0.0030 today, 0 securities are in the money (0.0% of shares on issue). No price up to ten times today’s switches on any more priced supply.
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 3.0M (16.4% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
- 15.4M more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| CHMAAH | Options | Price-triggered | $0.80 | 10 Oct 2028 | 250k | Filing |
| CHMAAJ | Options | Price-triggered | $0.60 | 31 Mar 2029 | 500k | Filing |
| CHMAAI | Options | Price-triggered | $0.50 | 31 Dec 2030 | 14.7M | Filing |
| CHMAAL | Warrants | Price-triggered, no exercise price stated | — | — | 700 | Filing |
| CHMAAB | Performance rights | Condition-triggered | — | — | 72k | Filing Meeting |
| CHMAY | Options | Price-triggered, no exercise price stated | — | — | 3.0M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
- CHMAAKconvertible notes41229 Sept 2026 Appendix 2A
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 19 Dec 2025 | Miles Prince | Other | — | 16.7M | — | — | 3Y notice |
| 19 Aug 2025 | Miles Prince | Buy on-market | 4.3M | — | — | — | 3Y notice |
| 26 June 2025 | Lesley Russell | Sell | — | 2.8M | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.